Home › Companies › ARROWHEAD PHARMACEUTICALS INC. › 2023-2024

ARROWHEAD PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and ARROWHEAD PHARMACEUTICALS INC.’s Form 8-K, filed March 19, 2024 (Item 5.07 on EDGAR). Page generated October 13, 2026.

9Reported items
291Asset managers
2,977Fund votes
March 14, 2024Meeting date

Results at a glance

Meeting of March 14, 2024: 7 items on ARROWHEAD PHARMACEUTICALS INC.’s Form 8-K, filed March 19, 2024: 7 without a stated outcome.

Material dissent

None.

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided · This season’s results screens

Proxy season: 2023-2024 2024-2025 2025-2026

Explore ARROWHEAD PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by ARROWHEAD PHARMACEUTICALS INC.

These tallies are ARROWHEAD PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed March 19, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ARROWHEAD PHARMACEUTICALS INC. — official shareholder meeting results, meeting held March 14, 2024
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Douglass Given	76,397,567	10,968,346	303,938	--	--	87%	Not verified	—
Elect Director: Michael S. Perry	82,446,900	4,911,855	311,096	--	--	94%	Not verified	—
Elect Director: Christopher Anzalone	84,313,696	2,976,660	379,495	--	--	97%	Not verified	—
Elect Director: Mauro Ferrari	81,342,884	6,020,799	306,168	--	--	93%	Not verified	—
Elect Director: Adeoye Olukoton	83,526,809	3,815,731	327,311	--	--	96%	Not verified	—
Elect Director: William Waddill	83,279,633	4,079,251	310,967	--	--	95%	Not verified	—
Elect Director: Victoria Vakiener	83,354,988	3,975,617	339,246	--	--	95%	Not verified	—

Source: ARROWHEAD PHARMACEUTICALS INC., Form 8-K, filed with the SEC on March 19, 2024 — read the filing on EDGAR.

How asset managers voted at the ARROWHEAD PHARMACEUTICALS INC. 2023-2024 meeting

Each item below shows how the 291 asset managers that disclosed a ARROWHEAD PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of ARROWHEAD PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Elect Director: Adeoye Olukoton

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 83,526,809AGAINST: 3,815,731

Details: description as filed, official tally, votes by 79 asset managers

Description as filed by funds: Election of Directors: Adeoye Olukotun

ARROWHEAD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Adeoye Olukoton”): 83,526,809 for, 3,815,731 against, per its Form 8-K filed March 19, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 79 asset managers below reported 42,027,042 for, 135,480 against, 38,587 abstained.

FOR

FOR: 42,027,042AGAINST: 135,480ABSTAIN: 38,587

Largest asset managers voting on “Election of Directors: Adeoye Olukotun” at ARROWHEAD PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	10,801,253	0	For
BlackRock	8,862,994	0	For
Fidelity	8,258,129	0	For
State Street	3,855,550	0	For
Capital Group	1,533,060	0	For
JPMorgan	1,422,450	0	For
Charles Schwab	970,877	0	For
Columbia Threadneedle	860,818	0	For
Equitable	454,285	0	For
AIG/SunAmerica	369,981	0	For
Jackson National	369,872	0	For
TIAA	327,657	0	For
T. Rowe Price	325,134	0	For
MUTUAL FUND SERIES TRUST	313,289	0	For
Dimensional	280,720	0	For
Invesco	216,044	0	For
Direxion Shares ETF Trust	211,712	0	For
QUANTITATIVE MASTER SERIES LLC	207,440	0	For
Voya	176,844	0	For
Russell Investments	172,870	0	For
Global X	168,934	0	For
CARILLON SERIES TRUST	156,618	0	For
Northern Trust	141,129	0	For
Lincoln Financial	135,237	0	For
Brighthouse	91,763	38,587	Mixed

Showing the 25 largest of 79 asset managers. See all 79 in the interactive database.

2. Elect Director: Christopher Anzalone

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 84,313,696AGAINST: 2,976,660

Details: description as filed, official tally, votes by 79 asset managers

Description as filed by funds: Election of Directors: Christopher Anzalone

ARROWHEAD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Christopher Anzalone”): 84,313,696 for, 2,976,660 against, per its Form 8-K filed March 19, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 79 asset managers below reported 42,153,040 for, 9,482 against, 38,587 abstained.

FOR

FOR: 42,153,040AGAINST: 9,482ABSTAIN: 38,587

Largest asset managers voting on “Election of Directors: Christopher Anzalone” at ARROWHEAD PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	10,801,253	0	For
BlackRock	8,862,994	0	For
Fidelity	8,258,129	0	For
State Street	3,855,550	0	For
Capital Group	1,533,060	0	For
JPMorgan	1,422,450	0	For
Charles Schwab	970,877	0	For
Columbia Threadneedle	860,818	0	For
Equitable	454,285	0	For
AIG/SunAmerica	369,981	0	For
Jackson National	369,872	0	For
TIAA	327,657	0	For
T. Rowe Price	325,134	0	For
MUTUAL FUND SERIES TRUST	313,289	0	For
Dimensional	280,720	0	For
Invesco	216,044	0	For
Direxion Shares ETF Trust	211,712	0	For
QUANTITATIVE MASTER SERIES LLC	207,440	0	For
Voya	176,844	0	For
Russell Investments	172,870	0	For
Global X	168,934	0	For
CARILLON SERIES TRUST	156,618	0	For
Northern Trust	141,129	0	For
Lincoln Financial	135,237	0	For
Brighthouse	91,763	38,587	Mixed

Showing the 25 largest of 79 asset managers. See all 79 in the interactive database.

3. Elect Director: Douglass Given

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%

FOR: 76,397,567AGAINST: 10,968,346

Details: description as filed, official tally, votes by 79 asset managers

Description as filed by funds: Election of Directors: Douglass Given

ARROWHEAD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Douglass Given”): 76,397,567 for, 10,968,346 against, per its Form 8-K filed March 19, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 87% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 79 asset managers below reported 37,110,234 for, 5,052,288 against, 38,587 abstained.

FOR

FOR: 37,110,234AGAINST: 5,052,288ABSTAIN: 38,587

Largest asset managers voting on “Election of Directors: Douglass Given” at ARROWHEAD PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	10,801,253	0	0	For
BlackRock	8,862,994	0	0	For
Fidelity	8,258,129	0	0	For
State Street	0	3,855,550	0	Against
Capital Group	1,533,060	0	0	For
JPMorgan	1,422,450	0	0	For
Charles Schwab	970,877	0	0	For
Columbia Threadneedle	0	860,818	0	Against
Equitable	454,285	0	0	For
AIG/SunAmerica	369,981	0	0	For
Jackson National	369,872	0	0	For
TIAA	327,657	0	0	For
T. Rowe Price	325,134	0	0	For
MUTUAL FUND SERIES TRUST	313,289	0	0	For
Dimensional	280,720	0	0	For
Invesco	216,044	0	0	For
Direxion Shares ETF Trust	211,712	0	0	For
QUANTITATIVE MASTER SERIES LLC	207,440	0	0	For
Voya	176,844	0	0	For
Russell Investments	172,870	0	0	For
Global X	168,934	0	0	For
CARILLON SERIES TRUST	156,618	0	0	For
Northern Trust	141,129	0	0	For
Lincoln Financial	6,774	128,463	0	Mixed
Brighthouse	91,763	0	38,587	Mixed

Showing the 25 largest of 79 asset managers. See all 79 in the interactive database.

4. Elect Director: Mauro Ferrari

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%

FOR: 81,342,884AGAINST: 6,020,799

Details: description as filed, official tally, votes by 79 asset managers

Description as filed by funds: Election of Directors: Mauro Ferrari

ARROWHEAD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Mauro Ferrari”): 81,342,884 for, 6,020,799 against, per its Form 8-K filed March 19, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 79 asset managers below reported 41,577,417 for, 585,105 against, 38,587 abstained.

FOR

FOR: 41,577,417AGAINST: 585,105ABSTAIN: 38,587

Largest asset managers voting on “Election of Directors: Mauro Ferrari” at ARROWHEAD PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	10,801,253	0	0	For
BlackRock	8,862,994	0	0	For
Fidelity	8,258,129	0	0	For
State Street	3,855,550	0	0	For
Capital Group	1,533,060	0	0	For
JPMorgan	1,422,450	0	0	For
Charles Schwab	970,877	0	0	For
Columbia Threadneedle	860,818	0	0	For
Equitable	454,285	0	0	For
AIG/SunAmerica	369,981	0	0	For
Jackson National	369,872	0	0	For
TIAA	327,657	0	0	For
T. Rowe Price	325,134	0	0	For
MUTUAL FUND SERIES TRUST	313,289	0	0	For
Dimensional	280,720	0	0	For
Invesco	216,044	0	0	For
Direxion Shares ETF Trust	211,712	0	0	For
QUANTITATIVE MASTER SERIES LLC	207,440	0	0	For
Voya	176,844	0	0	For
Russell Investments	172,870	0	0	For
Global X	0	168,934	0	Against
CARILLON SERIES TRUST	156,618	0	0	For
Northern Trust	0	141,129	0	Against
Lincoln Financial	135,237	0	0	For
Brighthouse	91,763	0	38,587	Mixed

Showing the 25 largest of 79 asset managers. See all 79 in the interactive database.

5. Elect Director: Michael S. Perry

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 82,446,900AGAINST: 4,911,855

Details: description as filed, official tally, votes by 79 asset managers

Description as filed by funds: Election of Directors: Michael S. Perry

ARROWHEAD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Michael S. Perry”): 82,446,900 for, 4,911,855 against, per its Form 8-K filed March 19, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 79 asset managers below reported 42,028,875 for, 133,647 against, 38,587 abstained.

FOR

FOR: 42,028,875AGAINST: 133,647ABSTAIN: 38,587

Largest asset managers voting on “Election of Directors: Michael S. Perry” at ARROWHEAD PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	10,801,253	0	For
BlackRock	8,862,994	0	For
Fidelity	8,258,129	0	For
State Street	3,855,550	0	For
Capital Group	1,533,060	0	For
JPMorgan	1,422,450	0	For
Charles Schwab	970,877	0	For
Columbia Threadneedle	860,818	0	For
Equitable	454,285	0	For
AIG/SunAmerica	369,981	0	For
Jackson National	369,872	0	For
TIAA	327,657	0	For
T. Rowe Price	325,134	0	For
MUTUAL FUND SERIES TRUST	313,289	0	For
Dimensional	280,720	0	For
Invesco	216,044	0	For
Direxion Shares ETF Trust	211,712	0	For
QUANTITATIVE MASTER SERIES LLC	207,440	0	For
Voya	176,844	0	For
Russell Investments	172,870	0	For
Global X	168,934	0	For
CARILLON SERIES TRUST	156,618	0	For
Northern Trust	141,129	0	For
Lincoln Financial	135,237	0	For
Brighthouse	91,763	38,587	Mixed

Showing the 25 largest of 79 asset managers. See all 79 in the interactive database.

6. Elect Director: Victoria Vakiener

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 83,354,988AGAINST: 3,975,617

Details: description as filed, official tally, votes by 79 asset managers

Description as filed by funds: Election of Directors: Victoria Vakiener

ARROWHEAD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Victoria Vakiener”): 83,354,988 for, 3,975,617 against, per its Form 8-K filed March 19, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 79 asset managers below reported 41,746,322 for, 414,041 against, 40,746 abstained.

FOR

FOR: 41,746,322AGAINST: 414,041ABSTAIN: 40,746

Largest asset managers voting on “Election of Directors: Victoria Vakiener” at ARROWHEAD PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	10,801,253	0	0	For
BlackRock	8,862,994	0	0	For
Fidelity	8,258,129	0	0	For
State Street	3,855,550	0	0	For
Capital Group	1,533,060	0	0	For
JPMorgan	1,422,450	0	0	For
Charles Schwab	970,877	0	0	For
Columbia Threadneedle	860,818	0	0	For
Equitable	454,285	0	0	For
AIG/SunAmerica	369,981	0	0	For
Jackson National	369,872	0	0	For
TIAA	327,657	0	0	For
T. Rowe Price	325,134	0	0	For
MUTUAL FUND SERIES TRUST	313,289	0	0	For
Dimensional	0	280,720	0	Against
Invesco	216,044	0	0	For
Direxion Shares ETF Trust	211,712	0	0	For
QUANTITATIVE MASTER SERIES LLC	207,440	0	0	For
Voya	176,844	0	0	For
Russell Investments	172,870	0	0	For
Global X	168,934	0	0	For
CARILLON SERIES TRUST	156,618	0	0	For
Northern Trust	141,129	0	0	For
Lincoln Financial	135,237	0	0	For
Brighthouse	91,763	0	38,587	Mixed

Showing the 25 largest of 79 asset managers. See all 79 in the interactive database.

7. Elect Director: William Waddill

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 83,279,633AGAINST: 4,079,251

Details: description as filed, official tally, votes by 79 asset managers

Description as filed by funds: Election of Directors: William Waddill

ARROWHEAD PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: William Waddill”): 83,279,633 for, 4,079,251 against, per its Form 8-K filed March 19, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

The 79 asset managers below reported 42,028,875 for, 133,647 against, 38,587 abstained.

FOR

FOR: 42,028,875AGAINST: 133,647ABSTAIN: 38,587

Largest asset managers voting on “Election of Directors: William Waddill” at ARROWHEAD PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	10,801,253	0	For
BlackRock	8,862,994	0	For
Fidelity	8,258,129	0	For
State Street	3,855,550	0	For
Capital Group	1,533,060	0	For
JPMorgan	1,422,450	0	For
Charles Schwab	970,877	0	For
Columbia Threadneedle	860,818	0	For
Equitable	454,285	0	For
AIG/SunAmerica	369,981	0	For
Jackson National	369,872	0	For
TIAA	327,657	0	For
T. Rowe Price	325,134	0	For
MUTUAL FUND SERIES TRUST	313,289	0	For
Dimensional	280,720	0	For
Invesco	216,044	0	For
Direxion Shares ETF Trust	211,712	0	For
QUANTITATIVE MASTER SERIES LLC	207,440	0	For
Voya	176,844	0	For
Russell Investments	172,870	0	For
Global X	168,934	0	For
CARILLON SERIES TRUST	156,618	0	For
Northern Trust	141,129	0	For
Lincoln Financial	135,237	0	For
Brighthouse	91,763	38,587	Mixed

Showing the 25 largest of 79 asset managers. See all 79 in the interactive database.

8. ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION.

No official match Fund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 3 wordings of this item as funds reported it.

98% Fund and manager reports combined; may count the same shares twice · no official result

FOR

Details: votes by 287 asset managers

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 78 asset managers voting on “ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION.” at ARROWHEAD PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	10,801,253	0	For
BlackRock	8,862,994	0	For
Fidelity	8,258,129	0	For
State Street	3,855,550	0	For
Capital Group	1,533,060	0	For
JPMorgan	1,422,450	0	For
Charles Schwab	970,877	0	For
Columbia Threadneedle	860,818	0	For
Equitable	454,285	0	For
AIG/SunAmerica	369,981	0	For
Jackson National	369,872	0	For
TIAA	327,657	0	For
T. Rowe Price	325,134	0	For
MUTUAL FUND SERIES TRUST	313,289	0	For
Dimensional	280,720	0	For
Invesco	216,044	0	For
Direxion Shares ETF Trust	211,712	0	For
QUANTITATIVE MASTER SERIES LLC	207,440	0	For
Voya	176,844	0	For
Russell Investments	172,870	0	For
Global X	168,934	0	For
CARILLON SERIES TRUST	156,618	0	For
Northern Trust	141,129	0	For
Lincoln Financial	135,237	0	For
Brighthouse	91,763	38,587	Mixed

Fund voting reports, all 78 managers: 42,105,703 for, 766 against, 38,587 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 236 asset managers voting on “ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION.” at ARROWHEAD PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Withheld	Vote
Lazard	19,000,000	0	0	For
Avoro Capital Advisors LLC	6,983,630	0	0	For
State Street	6,622,179	0	0	For
Fidelity	6,352,116	0	0	For
BlackRock	3,916,239	539	0	For
GEODE CAPITAL MANAGEMENT, LLC	2,634,955	0	0	For
UBS	1,651,047	0	0	For
Capital Group	1,533,060	0	0	For
Slate Path Capital LP	1,416,991	0	0	For
MELLON INVESTMENTS Corp	1,287,207	0	0	For
Avidity Partners Management LP	1,184,524	0	0	For
Charles Schwab	970,877	0	0	For
Aquilo Capital Management, LLC	0	0	908,474	Withhold
ORBIMED ADVISORS LLC	739,651	0	0	For
PICTET ASSET MANAGEMENT SA	624,000	0	0	For
T. Rowe Price	481,208	0	0	For
PRINCIPAL GLOBAL INVESTORS	470,038	0	0	For
Citadel	427,962	0	0	For
First Light Asset Management, LLC	425,963	0	0	For
Nuveen	362,857	0	0	For
Vanguard	343,784	0	0	For
EAGLE ASSET MANAGEMENT INC	323,495	0	0	For
JPMorgan	267,192	0	0	For
Invesco	262,693	0	0	For
AllianceBernstein	225,204	0	0	For

Institutional-manager reports, all 236 managers: 63,043,185 for, 734,422 against, 908,474 withheld, 11 abstained. Showing the 25 largest; see all in the interactive database.

9. TO RATIFY THE SELECTION OF KPMG LLP AS INDEPENDENT AUDITORS OF THE COMPANY FOR THE FISCAL YEAR ENDING SEPTEMBER 30…

No official matchAUDIT-RELATED

Combines 2 wordings of this item as funds reported it.

100% of fund votes cast · no official result

FOR

Details: description as filed, votes by 78 asset managers

Description as filed by funds: TO RATIFY THE SELECTION OF KPMG LLP AS INDEPENDENT AUDITORS OF THE COMPANY FOR THE FISCAL YEAR ENDING SEPTEMBER 30, 2024.

The 78 asset managers below reported 42,106,469 for, 38,587 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 42,106,469ABSTAIN: 38,587

Largest asset managers voting on “TO RATIFY THE SELECTION OF KPMG LLP AS INDEPENDENT AUDITORS OF THE COMPANY FOR THE FISCAL YEAR ENDING SEPTEMBE” at ARROWHEAD PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	10,801,253	0	For
BlackRock	8,862,994	0	For
Fidelity	8,258,129	0	For
State Street	3,855,550	0	For
Capital Group	1,533,060	0	For
JPMorgan	1,422,450	0	For
Charles Schwab	970,877	0	For
Columbia Threadneedle	860,818	0	For
Equitable	454,285	0	For
AIG/SunAmerica	369,981	0	For
Jackson National	369,872	0	For
TIAA	327,657	0	For
T. Rowe Price	325,134	0	For
MUTUAL FUND SERIES TRUST	313,289	0	For
Dimensional	280,720	0	For
Invesco	216,044	0	For
Direxion Shares ETF Trust	211,712	0	For
QUANTITATIVE MASTER SERIES LLC	207,440	0	For
Voya	176,844	0	For
Russell Investments	172,870	0	For
Global X	168,934	0	For
CARILLON SERIES TRUST	156,618	0	For
Northern Trust	141,129	0	For
Lincoln Financial	135,237	0	For
Brighthouse	91,763	38,587	Mixed

Showing the 25 largest of 78 asset managers. See all 78 in the interactive database.

Largest ARROWHEAD PHARMACEUTICALS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 107,500,000 shares outstanding at the time of that meeting.

Fund voting reports: top ARROWHEAD PHARMACEUTICALS INC. shareholders by shares voted on “Election of Directors: Adeoye Olukotun”, 2023-2024
#	Asset manager	% of shares outstanding
1	Vanguard	10.05%
2	BlackRock	8.24%
3	Fidelity	7.68%
4	State Street	3.59%
5	Capital Group	1.43%
6	JPMorgan	1.32%
7	Charles Schwab	0.90%
8	Columbia Threadneedle	0.80%
9	Equitable	0.42%
10	AIG/SunAmerica	0.34%

Institutional-manager reports: top ARROWHEAD PHARMACEUTICALS INC. shareholders by shares voted on “ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION.”, 2023-2024
#	Asset manager	% of shares outstanding
1	Lazard	17.67%
2	Avoro Capital Advisors LLC	6.50%
3	State Street	6.16%
4	Fidelity	5.91%
5	BlackRock	3.64%
6	GEODE CAPITAL MANAGEMENT, LLC	2.45%
7	UBS	1.54%
8	Capital Group	1.43%
9	Slate Path Capital LP	1.32%
10	MELLON INVESTMENTS Corp	1.20%

Reported ARROWHEAD PHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

ARROWHEAD PHARMACEUTICALS INC. holdings and ownership disclosed for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
BlackRock	18.81%	13F
Vanguard Group	14.92%	13F
State Street	6.10%	13F
FMR (Fidelity)	5.36%	13F
Christopher Anzalone	3.46%	DEF14A
Geode Capital	2.56%	13F
Goldman Sachs	1.70%	13F
Morgan Stanley	1.58%	13F
Northern Trust	1.21%	13F
Norges Bank	1.17%	13F

Percentages above are of 107,500,000 shares outstanding, as reported by ARROWHEAD PHARMACEUTICALS INC. on its Form 10-Q dated December 31, 2023 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ARROWHEAD PHARMACEUTICALS INC.’s 10-Q dated December 31, 2023. This page is a static snapshot rebuilt weekly on October 13, 2026; a live search always shows the current data.

At ARROWHEAD PHARMACEUTICALS INC.'s shareholder meeting held March 14, 2024, in the 2023-2024 proxy season, 291 asset managers reported how they voted in their SEC Form N-PX filings, covering 2,977 separate fund positions. Their filings are grouped here into 9 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. ARROWHEAD PHARMACEUTICALS INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION. — the reporting funds and managers cast 98% of the shares they voted in favour (FOR divided by FOR plus AGAINST plus WITHHELD; abstained and unvoted shares are excluded because neither took a side). Fund and manager reports are combined in it and may count the same shares twice: it adds fund reports to institutional-manager reports, which can cover the same shares. It is not the company's certified result.

ARROWHEAD PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Download data (CSV): ballot items · votes by manager · column guide.